Iopidine

Apraclonidine, the active ingredient in Iopidine, is a Alpha-2 adrenergic agonist presented as a ophthalmic solution for ocular use. It reduces intra‑ocular pressure and is indicated for glaucoma and ocular hypertension in adult patients. GNH USA supplies Iopidine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine is an Alpha‑2 adrenergic agonist used in the management of ocular pressure‑related disorders. - Glaucoma: lowers intra‑ocular pressure to help preserve visual field. - Ocular hypertension: reduces elevated eye pressure to prevent progression to glaucoma.

Iopidine may cause ocular and systemic reactions.

Common Side Effects: - Burning or stinging sensation upon instillation. - Redness of the conjunctiva. - Blurred vision temporarily after dosing. - Dry eye feeling. - Foreign body sensation. - Mild headache.

Serious or Rare Side Effects: - Allergic contact dermatitis of the eye. - Severe ocular inflammation or ulceration. - Systemic hypotension leading to dizziness. - Cardiac arrhythmia in susceptible patients. - Acute angle‑closure glaucoma precipitated by pupil dilation. - Vision loss due to optic nerve compromise.

Before prescribing Iopidine, clinicians should evaluate patient history and monitor ocular response. - Assess baseline intra‑ocular pressure: ensure appropriate reduction targets. - Monitor for systemic hypotension: especially in patients on antihypertensive therapy. - Use with caution in patients with cardiovascular disease or arrhythmias. - Avoid in individuals with known hypersensitivity to apraclonidine or any component of the formulation. - Do not combine with other ocular alpha‑agonists without specialist advice. - Store at room temperature: keep in original container, protect from light and moisture.

Iopidine can interact with other medications affecting ocular or systemic adrenergic pathways.

Major Interactions (Avoid): - Concurrent use of other ocular alpha‑2 agonists (e.g., brimonidine) may cause excessive IOP lowering. - Systemic monoamine oxidase inhibitors may increase risk of hypertensive episodes.

Moderate Interactions (Monitor Closely): - Systemic antihypertensive agents (beta‑blockers, ACE inhibitors) may potentiate hypotensive effects. - Topical non‑steroidal anti‑inflammatory eye drops may increase ocular irritation. - Certain anesthetic eye drops can alter absorption and efficacy.